Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g BRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
Patricia A GanzHanna BandosTanja ŠpanićSue FriedmanVolkmar MuellerSherko KuemmelSuzette DelalogeEtienne G C BrainMasakazu ToiHideko YamauchiE Martínez de DueñasAnne ArmstrongSeock-Ah ImChuan-Gui SongHong ZhengTomasz SarosiekPriyanka SharmaCuizhi GengPeifen FuKerstin RhiemHeike Frauchiger-HeuerPauline WimbergerDaphné t'Kint de RoodenbekeNing LiaoAnnabel GoodwinCamille Chakiba-BrugèreMichael L FriedlanderKeun Seok LeeSylvie GiacchettiToshimi TakanoFernando HenaoShamsuddin ViraniFrances Valdes-AlbiniSusan M DomchekCharles BaneEdward C McCarronMonica MitaGiovanna RossiPriya RastogiAnitra FieldingRichard D GelberElsemieke D ScheepersDavid A CameronJudy E GarberCharles E GeyerAndrew N J TuttPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Treatment-emergent symptoms from OL were limited, generally resolving after treatment ended. OL- and PL-treated patients had similar functional scores, slowly improving during the 24 months after (N)ACT and there was no clinically meaningful persistence of fatigue severity in OL-treated patients.
Keyphrases
- patient reported outcomes
- phase iii
- end stage renal disease
- epidermal growth factor receptor
- newly diagnosed
- double blind
- ejection fraction
- open label
- clinical trial
- chronic kidney disease
- endothelial cells
- early stage
- peritoneal dialysis
- prognostic factors
- advanced non small cell lung cancer
- sleep quality
- study protocol